Canagliflozin serves as an SGLT2 inhibitor for managing glycemic states in individuals. Inhibition of renal glucose reabsorption promotes healthy sugar disposal through the urinary excretory system.
Canagliflozin belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class. The compound works by limiting the reabsorption of glucose in the kidneys, which helps lower blood-sugar levels in people with type 2 diabetes. It appears as the active substance in several marketed products, most notably the brand name Invokana, which is approved for use in Singapore by the Health Sciences Authority.
Invokana is available as oral tablets in strengths such as 100 mg and 300 mg. The drug is also supplied in generic versions that contain the same active compound but may differ in excipients or packaging. In Singapore, both brand-named and generic tablets are dispensed through pharmacies and hospitals, following the same regulatory standards.
The primary indication for this SGLT2 inhibitor is the management of type 2 diabetes mellitus. It is commonly added when diet, exercise, and first-line agents do not achieve target glucose levels. Some clinicians also consider it for patients who would benefit from modest weight reduction and a small drop in blood pressure, effects that are often observed with this class of medication. Typical candidates include adults with established diabetes who have adequate kidney function.
After ingestion, the compound reaches the kidneys where it blocks the SGLT2 proteins responsible for pulling glucose back into the bloodstream. By inhibiting this pathway, excess glucose is expelled in the urine, which reduces overall blood-glucose concentrations. The action is independent of insulin, so it can complement other glucose-lowering therapies without relying on pancreatic function.
Mild symptoms such as increased urination, genital yeast infections, and occasional dizziness are reported across Canagliflozin medications. These effects usually resolve on their own or with simple measures like good hygiene and adequate fluid intake.
Infrequent but significant events may include dehydration, low blood pressure, or signs of a urinary-tract infection that spreads. A small number of users experience ketoacidosis, a condition that requires prompt medical attention. Any sudden change in mental status, rapid breathing, or unusual fatigue should be taken seriously.
People with severe kidney impairment, those on dialysis, or individuals with a history of frequent yeast infections should use this agent only under professional guidance. Pregnant or breastfeeding individuals are generally advised to avoid SGLT2 inhibitors, as safety data are limited.
Canagliflozin can enhance the glucose-lowering effect of insulin or sulfonylureas, increasing the risk of hypoglycaemia. Alcohol consumption may also raise the chance of dehydration. Certain diuretics and blood-pressure medicines can compound the drop in blood pressure, so a review of all current treatments is advisable. Specific interaction lists are available on individual medication pages.
Tablets should be stored at room temperature, away from moisture and direct sunlight. The drug is usually taken once daily, with or without food, and treatment length may vary-from a few months for initial glucose control to indefinite use for long-term management. For precise dosing schedules, strength selection, and duration, refer to the clinical information supplied with the specific product.
This article provides an educational overview of Canagliflozin as an active substance and does not constitute medical advice. Individual medicines that contain this compound, such as Invokana, may differ in formulation, strength, and usage directions. The information presented here is not intended to replace the label details of any specific product, and liability for clinical decisions rests with the user. Patients should read the medication label and seek guidance from a qualified healthcare professional for personalized recommendations.
